New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
08:50 EDTRPRXRepros Therapeutics weakness creates buying opportunity, says Roth Capital
After Repros' stock sold off yesterday, Roth Capital spoke with the company's management and is more confident that the outlook for the company's Androxal drug remains positive. The firm maintains a $19 price target and Buy rating on the stock.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RPRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use